This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tamargo, R. J. Articles by Brem, H. Search for Related Content PubMed PubMed Citation Articles by Tamargo, R. J. Articles by Brem, H.

Angiogenesis Inhibition by Minocycline¹

Department of Neurological Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

We describe a new inhibitor of angiogenesis, minocycline, a semisynthetic tetracycline antimicrobial with anticollagenase properties. Minocycline was incorporated into controlled release polymers and tested in the rabbit cornea against neovascularization in the presence of the VX2 carcinoma. Inhibition by minocycline was shown to be comparable to that of the combination of heparin and cortisone, a potent inhibitor of angiogenesis. Minocycline decreased tumor-induced angiogenesis by a factor of 4.5, 4.4, and 2.9 at 7, 14, and 21 days, respectively. At the end of the experiment, whereas the corneas with empty polymers had large, invasive, exophytic tumors, none of the corneas with minocycline had such vascular masses. Recently, studies of agents that disrupt collagen synthesis and deposition have yielded several new angiogenesis inhibitors. We suggest that investigation of agents that disrupt collagenolysis may similarly identify other angiogenesis inhibitors and further clarify the mechanisms of angiogenesis.

¹ This work was supported in part by The Association for Brain Tumor Research Fellowship in Memory of Steven Lowe, by NIH Grant NS01058, and by the Andrew W. Mellon Foundation Johns Hopkins University Faculty Development Award.

² Present address: Department of Medicine, University of Minnesota, 420 Delaware Street, Southeast, Minneapolis, MN 55455.

³ To whom requests for reprints should be addressed, at Johns Hopkins Hospital/Meyer 7-113, 600 N. Wolfe Street, Baltimore, MD 21205.

Received 6/15/90. Accepted 10/24/90.

This article has been cited by other articles:

				S. S. Bhandarkar, C. Cohen, M. Kuruvila, T. H. Rea, J. B. MacKelfresh, D. J. Lee, R. L. Modlin, and J. L. Arbiser Angiogenesis in Cutaneous Lesions of Leprosy: Implications for Treatment Arch Dermatol, December 1, 2007; 143(12): 1527 - 1529. [Abstract] [Full Text] [PDF]

				G. C. Daginakatte and D. H. Gutmann Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth Hum. Mol. Genet., May 1, 2007; 16(9): 1098 - 1112. [Abstract] [Full Text] [PDF]

				J. S. Yao, Y. Chen, W. Zhai, K. Xu, W. L. Young, and G.-Y. Yang Minocycline Exerts Multiple Inhibitory Effects on Vascular Endothelial Growth Factor-Induced Smooth Muscle Cell Migration: The Role of ERK1/2, PI3K, and Matrix Metalloproteinases Circ. Res., August 20, 2004; 95(4): 364 - 371. [Abstract] [Full Text] [PDF]

				M. P. Bendeck, M. Conte, M. Zhang, N. Nili, B. H. Strauss, and S. M. Farwell Doxycycline Modulates Smooth Muscle Cell Growth, Migration, and Matrix Remodeling after Arterial Injury Am. J. Pathol., March 1, 2002; 160(3): 1089 - 1095. [Abstract] [Full Text] [PDF]

				M. Simons, R. O. Bonow, N. A. Chronos, D. J. Cohen, F. J. Giordano, H. K. Hammond, R. J. Laham, W. Li, M. Pike, F. W. Sellke, et al. Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus : An Expert Panel Summary Circulation, September 12, 2000; 102 (11): e73 - e86. [Abstract] [Full Text] [PDF]

				J. Liu, B. Razani, S. Tang, B. I. Terman, J. A. Ware, and M. P. Lisanti Angiogenesis Activators and Inhibitors Differentially Regulate Caveolin-1 Expression and Caveolae Formation in Vascular Endothelial Cells. ANGIOGENESIS INHIBITORS BLOCK VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED DOWN-REGULATION OF CAVEOLIN-1 J. Biol. Chem., May 28, 1999; 274(22): 15781 - 15785. [Abstract] [Full Text] [PDF]

				L.M. Golub, H.-M. Lee, M.E. Ryan, W.V. Giannobile, J. Payne, and T. Sorsa Tetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial Mechanisms Advances in Dental Research, November 1, 1998; 12(1): 12 - 26. [Abstract] [PDF]

				R.S. Fife and G.W. Sledge JR Effects of Doxycycline on Cancer Cells in Vitro and in Vivo Advances in Dental Research, November 1, 1998; 12(1): 94 - 96. [PDF]

				V. W. Li, M. P. Jaffe, W. W. Li, and H. A. Haynes Off-Label Dermatologic Therapies: Usage, Risks, and Mechanisms Arch Dermatol, November 1, 1998; 134(11): 1449 - 1454. [Abstract] [Full Text] [PDF]

				L. M. Golub, N.S. Ramamurthy, T. F. McNamara, R. A. Greenwald, and B. R. Rifkin Tetracyclines Inhibit Connective Tissue Breakdown: New Therapeutic Implications for an Old Family of Drugs Critical Reviews in Oral Biology & Medicine, January 1, 1991; 2(3): 297 - 321. [Abstract] [Full Text] [PDF]